Real-World study tracks HyQvia use in myeloma patients with weakened immunity

NCT ID NCT05879757

Recruiting now Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 75 multiple myeloma patients with secondary immunodeficiency who are receiving HyQvia as part of their routine care. Researchers will collect data on infusion details like dose, rate, and site, as well as any reasons for stopping or switching treatment. The goal is to understand how HyQvia is used in real-world settings, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HyQvia (immune globulin infusion 10% with recombinant human hyaluronidase)
What this could lead to: If successful, this study could provide practical guidance on how to best administer HyQvia to multiple myeloma patients with weakened immune systems.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary across different clinics and patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA SECONDARY IMMUNODEFICIENCY (SID)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

A.O.U.C Policlinico di Bari
RECRUITING

Bari, 70124, Italy
AOU Policlinico Rodolico San Marco
RECRUITING

Catania, 95125, Italy
Alexandra General Hospital
RECRUITING

Athens, 11528, Greece
Ankara University Medical Faculty
RECRUITING

Ankara, 06100, Turkey (Türkiye)
Antalya Training and Research Hospital
RECRUITING

Antalya, 7100, Turkey (Türkiye)
Azienda Ospedale Universita Padova
NOT_YET_RECRUITING

Padova, 35128, Italy
CHU Amiens - Hopital Sud
RECRUITING

Salouël, Somme, 80480, France
CHU Bordeaux - Hopital Haut-Leveque
NOT_YET_RECRUITING

Pessac, 33604, France
CHU Dijon - Hopital du Bocage
NOT_YET_RECRUITING

Dijon, 21079, France
Fakultni nemocnice Plzen
RECRUITING

Pilsen, 30460, Czechia
General Hospital of Thessaloniki "G. Papanikolaou"
RECRUITING

Thessaloniki, 57010, Greece
Hopital Prive du Confluent
RECRUITING

Nantes, 44 277, France
Hopital de la Source - CHR Orleans
NOT_YET_RECRUITING

Orléans, 45067, France
Hospital Clinico San Carlos
RECRUITING

Madrid, 28040, Spain
Hospital Universitari Son Espases
RECRUITING

Palma, 70120, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Instituto Privado de Investigaciones Clinicas de Cordoba
WITHDRAWN

Córdoba, X5000AAW, Argentina
Institutul Clinic Fundeni
NOT_YET_RECRUITING

Bucharest, 22328, Romania
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca
NOT_YET_RECRUITING

Cluj-Napoca, 400015, Romania
Istanbul Universitesi
NOT_YET_RECRUITING

Istanbul, 34098, Turkey (Türkiye)
Lund University Hospital
NOT_YET_RECRUITING

Lund, SE-221 85, Sweden
MHP-Muenchner Haematologiepraxis
NOT_YET_RECRUITING

Berlin, 10117, Germany
Pomorski Uniwersytet Medyczny
RECRUITING

Szczecin, 71252, Poland
Spitalul Clinic Colentina
NOT_YET_RECRUITING

Bucharest, 020125, Romania
Spitalul Clinic Municipal Filantropia Craiova
NOT_YET_RECRUITING

Craiova, 200143, Romania
University of Padova
RECRUITING

Treviso, 31122, Italy
Vseobecna fakultni Nemocnice
NOT_YET_RECRUITING

Prague, 128 08, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.